NasdaqCM - Delayed Quote USD

Curis, Inc. (CRIS)

14.47

-0.05

(-0.34%)

At close: April 26 at 4:00 PM EDT

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2024, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 8,550 shares of Curis common stock to a new employee, with a grant date of April 1, 2024 (the "Q2 2024 Inducement Grant").

PR Newswire 22 days ago
Curis to Present at Upcoming Healthcare Conferences in April

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the 23rd Annual Needham Virtual Healthcare Conference being held on April 8 - 11, 2024. Presentation details are as follows:

PR Newswire 23 days ago
Curis Provides Fourth Quarter 2023 Business Update

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2023.

PR Newswire 2 months ago
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its fourth quarter 2023 financial results on Thursday, February 8, 2024, at 8:00 a.m. ET. Management will host a conference call at 8:30 a.m. ET.

PR Newswire 2 months ago
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced initial combination study data from its TakeAim Lymphoma trial including 5 primary CNS lymphoma (PCNSL) patients.

PR Newswire 4 months ago
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, last night presented clinical data from its TakeAim Leukemia Study at the 2023 ASH Conference.

PR Newswire 4 months ago
Curis Announces Three Presentations at ASH

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company along with its collaborative partners will be presenting three posters at the upcoming 65th ASH Annual Meeting and Exposition (ASH 2025) being held in San Diego, California and online from December 9th to December 12th.

PR Newswire 4 months ago
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into an investigator-initiated clinical trial agreement with the University of Florida to study the combination of emavusertib and pembrolizumab in patients with metastatic melanoma.

PR Newswire 4 months ago
Curis Provides Third Quarter 2023 Business Update

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today reported its business update and financial results for the quarter ended September 30, 2023.

PR Newswire 5 months ago
Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that the Company will release its third quarter 2023 financial results on Thursday, November 2, 2023, at 8:00 a.m. ET. Management will host a conference call on the same day at 8:30 a.m. ET.

PR Newswire 5 months ago
Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced the 2nd Symposium on IRAK4 in Cancer taking place virtually on September 22, 9:00am-1:00pm ET.

PR Newswire 7 months ago
Curis to Present at Upcoming Healthcare Conferences in September

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences:

PR Newswire 7 months ago
Curis Provides Second Quarter 2023 Business Update

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today reported its business update and financial results for the second quarter ended June 30, 2023.

PR Newswire 8 months ago
Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that the Company will release its second quarter 2023 financial results on Thursday, August 3, 2023, after the close of U.S. markets. Management will host a conference call on the same day at 4:30 p.m. ET.

PR Newswire 8 months ago
FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID

Curis, Inc., (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibitor (IRAK4, FLT3 and CLK) for the treatment of hematologic malignancies, today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the TakeAim Leukemia Phase 1/2 study of emavusertib. Further, the recommended phase 2 dose (RP2D) for emavusertib as a monotherapy has been established at 300 mg BID in p

PR Newswire 9 months ago
Curis Announces $15.1 Million Registered Direct Offering

Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, a triple target inhibitor (IRAK4, FLT3 and CLK) for the treatment of hematologic malignancies, today announced that it has entered into definitive agreements led by existing investors for the purchase of 18.4 million of its shares of common stock at a purchase price of $0.82 per share in a registered direct offering priced at-the-market under Nasdaq rules.

PR Newswire 9 months ago
Curis Provides First Quarter 2023 Business Update

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its business update and financial results for the first quarter ended March 31, 2023.

PR Newswire 11 months ago

Performance Overview

Return	CRIS	S&P 500
YTD	+13.49%	+6.92%
1-Year	+1,755.13%	+25.26%
3-Year	+36.51%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Curis, Inc. (CRIS)

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis to Present at Upcoming Healthcare Conferences in April

Curis Provides Fourth Quarter 2023 Business Update

Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024

Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference

Curis Announces Three Presentations at ASH

Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma

Curis Provides Third Quarter 2023 Business Update

Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023

Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer

Curis to Present at Upcoming Healthcare Conferences in September

Curis Provides Second Quarter 2023 Business Update

Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023

FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID

Curis Announces $15.1 Million Registered Direct Offering

Curis Provides First Quarter 2023 Business Update

Performance Overview